Navigation Links
Transgenomic Reports First Quarter Financial Results
Date:5/12/2011

OMAHA, Neb., May 12, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the three months ended March 31, 2011, and provided a business update.

First Quarter Financial Results

Net sales for the first quarter of 2011 were $7.5 million, an increase of 37 percent compared with $5.4 million for the same period in 2010. Gross profit was $4.2 million or 56 percent of net sales, compared with gross profit of $2.9 million or 53 percent of net sales for the same period in 2010. 

The increase in revenue is primarily due to our recent acquisition of the FAMILION family of genetic tests on December 29, 2010, as we operated this business the entire quarter.  

Operating expenses were $4.9 million during the first quarter of 2011, compared with $3.3 million in the prior year. This increase in operating expenses is directly related to our FAMILION lab, including noncash charges totaling $300,000 relating to the amortization of the acquired intangibles.  

The net loss for the first quarter of 2011 was $2.8 million or $0.06 per share compared with a net loss of $324,000 or $0.01 per share for the first quarter of 2010. This was due primarily to the noncash Preferred Stock expenses, totaling $2.0 million, and the amortization of the acquired intangible assets, which totaled $300,000.  Absent these expenses, our net loss would have been $460,000 for the first quarter of 2011.

Modified EBITDA improved to ($16,000) in the first quarter of 2011 from ($209,000) in the first quarter of 2010.

Cash and cash equivalents were $3.2 million as of March 31, 2011, compared with $3.5 million as of December 31, 2010.

Comment and Outlook"We are quite pleased with the quarter's results in both top-line growth and EBITDA improvement," commented Craig Tuttle, President and Chief Executive Officer
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
3. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
4. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
5. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
6. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Transgenomic Reports Fourth Quarter Financial Results
10. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
11. Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
(Date:1/14/2014)... Pa. , Jan. 14, 2014 Dynamic Healthcare Services, ... announced today that it acquired Progressive Home Medical Equipment, Inc. ... 7, 2014. The terms of the acquisition were not disclosed. ... equipment ("DME") company providing a wide range of sleep, mobility, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... PCYC ) today reported financial results for its fiscal year ... During the fiscal year ended June 30, 2010, total revenue recognized ... fiscal year ended June 30, 2009.  The GAAP net loss reported ... or $0.31 per share. This compares to a GAAP net loss ...
... Sept. 13 Amgen (Nasdaq: AMGN ) will ... 2010, at the St. Regis New York in New York ... Ph.D., vice president of Global Development, for Amgen, will present ... available over the Internet and can be accessed from Amgen,s ...
Cached Medicine Technology:Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 3Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 4Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 5Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 6Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 7Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 8Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 9Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 10Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 11Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 12Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 13Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 14
(Date:4/23/2014)... vegetables are often displayed in the popular Swedish ... plenty of high-sugar foods. A new study from ... portrayed in children,s TV programmes as well as ... habits and weight status. , Steingerdur Olafsdottir,s doctoral ... the popular Swedish children,s TV show Bolibompa. Healthy ...
(Date:4/23/2014)... an increase in adolescents, marijuana use following the legalization ... According to a new study at Rhode Island Hospital ... with and without medical marijuana laws, legalizing the drug ... study is published online in advance of print in ... "Any time a state considers legalizing medical marijuana, there ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... been shown to reduce seizures in patients with medication-resistant ... with an innovative electrode placement planning system developed by ... of seizures in nearly half of the implanted Rush ... good news for a large portion of the nearly ... seizures can,t be controlled with medications and who are ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
Breaking Medicine News(10 mins):Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... the cure for certain types of antibiotic-resistant bowel bacteria, ... ,Overuse of antibiotics has led to colonisation of the ... are responsible for persistent and transmissible infections. ... a beneficial effect on human gut health by helping ...
... Final results from a multi-center study shows that repeated ... is well tolerated and results in a significant ... in upper limbs following stroke, according to research from ... ,Significant improvements in these outcome measures indicate ...
... Luiz Inacio Lula da Silva has allowed his country to ... and opted for a cheaper generic alternative from India. ... be able to import generic versions of Efavirenz from three ... will be 72 percent lower than the price charged by ...
... head yet again, this time on what kind of dress is ... linen , but denim and wool, Swiss researchers say after reviewing ... skin. ,Writing in a study published online by ... ,The team from the Triemli Hospital, Zurich, Switzerland, ...
... nearest medic? Not to worry. A team from Sheffield Hallam University ... that can protect damaged bones and aid their recovery. ... isolated conditions which are difficult for medical teams to reach. ... those who are injured taking part in snow sports. It is ...
... older Americans diagnosed with primary open angle glaucoma (POAG) ... according to a study. ,The study ... U.S. to utilize longitudinal data from a nationally representative ... glaucoma medication use and surgeries among adults aged 65 ...
Cached Medicine News:Health News:Pain and Intensity Of Post-stroke Spasticity Decreased by Botox Treatment 2Health News:Denim, Not Cotton, Apt Wear for Summer 2
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... HEp-2000 ANA uses a patented HEp-2 cell ... increase the sensitivity to SS-A/Ro autoantibodies, without ... independent studies have been published worldwide on ... sensitivity to SS-A/Ro autoantibodies when used in ...
... and ENA assays can be used ... antinuclear antibodies, which are associated with ... Systemic lupus erythematosus (Lupus), Sjgren's syndrome, ... sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's ...
Medicine Products: